|
CV Information
 PROFESOR MADYA DR. NAZRI MUSTAFFA
| |
|---|---|
|
Grant's Name,"Project's Title" (Research Period)(Role)[Sponsorship]
| |
| 1 | , "RISA UC M16-066 A STUDY TO ASSESS THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH ULCERATIVE COLITIS WHO RESPONDED TO INDUCTION TREATMENT IN M16-067 OR M16-065" (01.10.2018 - 01.10.2019) [ Abbvie ] - Source: HCMSv3 |
| 2 | , "RISA CD M16-000 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED 52-WEEK MAINTENANCE AND AN OPEN-LABEL EXTENSION STUDY OF THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH CROHN'S DISEASE WHO RESPONDED TO INDUCTION TREATMENT IN M16-" (10.04.2018 - 10.10.2019) [ Abbvie ] - Source: HCMSv3 |
| 3 | , "RISA CD M16-006 A STUDY OF THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE" (10.04.2018 - 10.10.2019) [ Abbvie ] - Source: HCMSv3 |
| 4 | , "RISA CD M15-991 A STUDY TO ASSESS THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO FAILED PRIOR BIOLOGIC TREATMENT" (10.04.2018 - 10.10.2019) [ Abbvie ] - Source: HCMSv3 |
| 5 | , "GED-0301-CD-003 "A STUDY OF EFFICACY AND SAFETY OF MONGERSEN (GED-0301) FOR THE TREATMENT OF ADULT AND ADOLESCENT SUBJECTS WITH ACTIVE CROHN'S DISEASE"" (28.07.2017 - 28.07.2018) [ Celgene Corporation ] - Source: HCMSv3 |
| 6 | , "GED-0301-CD-004 “A PHASE 3, LONGTERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHN’S DISEASE�" (28.07.2017 - 28.07.2018) [ Celgene Corporation ] - Source: HCMSv3 |
| 7 | , "CELGENE GED-0301-CD-002 TRIAL “A PHASE 3,RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MONGERSEN (GED-0301) FOR THE TREATMENT OF SUBJECTS WITH ACTIVE CROHN’S DISEASE�" (27.05.2016 - 26.05.2017) (03) [ Celgene Group ] - Source: HCMSv3 |